PTGX Protagonist Therapeutics, Inc. Stock Quote

PTGX [NASD]

Index	-	P/E	-	EPS (ttm)	-2.59	Insider Own	1.70%	Shs Outstand	48.75M	Perf Week	0.13%
Market Cap	375.24M	Forward P/E	-	EPS next Y	-3.64	Insider Trans	-1.81%	Shs Float	47.96M	Perf Month	-16.47%
Income	-122.50M	PEG	-	EPS next Q	-0.93	Inst Own	-	Short Float	6.97%	Perf Quarter	-67.59%
Sales	46.90M	P/S	8.00	EPS this Y	-40.90%	Inst Trans	2.50%	Short Ratio	2.86	Perf Half Y	-77.34%
Book/sh	6.19	P/B	1.27	EPS next Y	-17.00%	ROA	-33.30%	Target Price	43.57	Perf Year	-77.48%
Cash/sh	6.40	P/C	1.23	EPS next 5Y	-	ROE	-38.00%	52W Range	7.39 - 50.54	Perf YTD	-77.02%
Dividend	-	P/FCF	-	EPS past 5Y	-1.00%	ROI	-41.90%	52W High	-84.45%	Beta	2.59
Dividend %	-	Quick Ratio	7.90	Sales past 5Y	-	Gross Margin	-	52W Low	6.36%	ATR	0.95
Employees	122	Current Ratio	7.90	Sales Q/Q	314.50%	Oper. Margin	-	RSI (14)	24.97	Volatility	5.15% 7.98%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	20.90%	Profit Margin	-	Rel Volume	0.81	Prev Close	7.70
Shortable	Yes	LT Debt/Eq	0.00	Earnings	May 04 AMC	Payout	-	Avg Volume	1.17M	Price	7.86
Recom	1.60	SMA20	-10.27%	SMA50	-55.01%	SMA200	-72.76%	Volume	943,290	Change	2.08%

Feb-11-22

Initiated

BTIG Research

Buy

$55

Oct-12-21

Upgrade

JP Morgan

Neutral → Overweight

$49 → $55

Oct-11-21

Upgrade

Northland Capital

Market Perform → Outperform

$40

Sep-20-21

Downgrade

JP Morgan

Overweight → Neutral

$60 → $49

May-24-21

Initiated

Northland Capital

Outperform

$42

May-24-21

Initiated

JMP Securities

Mkt Outperform

$48

Jan-06-21

Initiated

JP Morgan

Overweight

Dec-16-20

Initiated

Piper Sandler

Overweight

$53

Sep-18-20

Reiterated

H.C. Wainwright

Buy

$28 → $33

Jul-15-20

Initiated

Jefferies

Buy

$27

May-18-20

Reiterated

H.C. Wainwright

Buy

$23 → $28

Jul-08-19

Initiated

H.C. Wainwright

Buy

$23

May-09-19

Upgrade

Stifel

Hold → Buy

$11 → $17

Dec-06-18

Initiated

Nomura

Buy

$13

Jan-29-18

Initiated

Stifel

Buy

$32

Jul-21-17

Initiated

BTIG Research

Buy

$36

May-11-22 08:13AM	7 Micro-Cap Stocks to Buy and Hold for the Next 10 Years InvestorPlace -12.66%
06:16AM	Industry Analysts Just Upgraded Their Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Revenue Forecasts By 28% Simply Wall St.
May-04-22 06:35PM	Protagonist Therapeutics (PTGX) Reports Q1 Loss, Tops Revenue Estimates Zacks
04:05PM	Protagonist Reports First Quarter 2022 Financial Results and Provides Corporate Update PR Newswire
01:29PM	Shareholders in Protagonist Therapeutics (NASDAQ:PTGX) are in the red if they invested a year ago Simply Wall St.
Apr-27-22 12:44PM	Biotech Stock Roundup: GILD's COVID-19 Drug Update, AXSM Down on Regulatory News Zacks
Apr-26-22 08:38AM	Protagonist Therapeutics shares slid after sharing Phase 2 data for its experimental ulcerative colitis treatment MarketWatch -49.95%
Apr-25-22 04:25PM	Protagonist Therapeutics Announces Topline Data from Phase 2 IDEAL Study of PN-943 in Ulcerative Colitis PR Newswire
Apr-19-22 04:15PM	Protagonist Therapeutics Reports Granting of Inducement Awards PR Newswire
Apr-14-22 05:44PM	Why this East Bay biotech lost nearly 22% of its value American City Business Journals -21.83%
04:17PM	Protagonist Therapeutics Dives As Its Drama Continues With A New FDA Concern Investor's Business Daily
08:27AM	Protagonist's stock falls 27% after updating investors about experimental blood disorder drug MarketWatch
06:31AM	FDA Intends To Revoke Protagonist Therapeutics' Rusfertide Breakthrough Tag In Rare Form Of Blood Cancer Benzinga
Mar-28-22 07:06AM	Protagonist Therapeutics Announces Appointment of Asif Ali as Executive Vice President and Chief Financial Officer PR Newswire
Mar-16-22 07:00AM	Protagonist Therapeutics Earns $25 Million Milestone Payment from Janssen Biotech for Dosing of Third Patient in Phase 2b Clinical Trial of PN-235 in Moderate-to-Severe Plaque Psoriasis PR Newswire
Feb-28-22 06:15PM	Protagonist Therapeutics (PTGX) Reports Q4 Loss, Tops Revenue Estimates Zacks
04:05PM	Protagonist Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Update PR Newswire
Feb-24-22 05:40PM	Vir Biotechnology, Inc. (VIR) Q4 Earnings and Revenues Beat Estimates Zacks
Feb-16-22 10:39AM	3 Desirable Drug Stocks With Very Promising Pipelines InvestorPlace -7.07%
05:26AM	Protagonist Therapeutics (PTGX) Soars 5%: Is Further Upside Left in the Stock? Zacks
Feb-10-22 07:00AM	Protagonist Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference PR Newswire
Feb-07-22 12:44PM	We're Hopeful That Protagonist Therapeutics (NASDAQ:PTGX) Will Use Its Cash Wisely Simply Wall St.
Jan-19-22 04:30AM	5 Biotech Stocks That Are Bucking the Selloff Barrons.com
Jan-12-22 11:26AM	Protagonist Therapeutics, Inc. (PTGX) Fell Out Of Favor With Hedge Funds Insider Monkey
Jan-04-22 12:24PM	/C O R R E C T I O N -- Protagonist Therapeutics, Inc./ PR Newswire
Dec-23-21 12:38PM	Rtw Investments, Lp Buys Thermo Fisher Scientific Inc, Penumbra Inc, Tenaya Therapeutics Inc, ... GuruFocus.com
Dec-12-21 09:30AM	Protagonist Therapeutics Presents Updated Phase 2 Rusfertide Data in Polycythemia Vera (PV) at ASH 2021 Annual Meeting PR Newswire
Dec-03-21 07:00AM	Protagonist Therapeutics to Present at the JMP Securities Hematology and Oncology Summit PR Newswire
Dec-02-21 04:05PM	Protagonist Therapeutics Announces the Selection of Oral Peptide PN-235 into Phase 2 Clinical Development Program for Multiple Indications PR Newswire +5.69%
Nov-15-21 07:00AM	Protagonist Therapeutics Announces Positive Phase 2a Data Supporting the Potential Use of Rusfertide as a First-in-Class Therapy in Hereditary Hemochromatosis PR Newswire
Nov-11-21 07:00AM	Protagonist Therapeutics to Participate in Two Upcoming Healthcare Investor Conferences PR Newswire
Nov-08-21 08:12AM	Why Protagonist Therapeutics Stock Skyrocketed 80.2% Last Month Motley Fool
Nov-04-21 07:00AM	Protagonist Therapeutics Announces Updated Data from Phase 2 Study of Rusfertide in Polycythemia Vera Selected for Oral Presentations at the ASH 2021 Annual Meeting PR Newswire
Nov-03-21 06:25PM	Protagonist Therapeutics (PTGX) Reports Q3 Loss, Tops Revenue Estimates Zacks
04:05PM	Protagonist Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update PR Newswire
Oct-27-21 03:03PM	Analysts Estimate Protagonist Therapeutics (PTGX) to Report a Decline in Earnings: What to Look Out for Zacks
Oct-26-21 07:00AM	Protagonist Therapeutics Earns $7.5 Million Milestone Payment from IL-23 Receptor Collaboration with Janssen PR Newswire
Oct-18-21 06:09AM	Hedge Funds Are Crazy About Protagonist Therapeutics, Inc. (PTGX) Insider Monkey
Oct-14-21 09:27AM	New Strong Sell Stocks for October 14th Zacks
Oct-13-21 08:25PM	J.P. Morgan Says Theres Room for Over 40% Upside in These 2 Stocks TipRanks
Oct-12-21 07:00AM	Protagonist Therapeutics to Present at the Jefferies Next Generation IBD Therapeutics Summit PR Newswire -10.29%
05:01AM	46 Biggest Movers From Yesterday Benzinga
Oct-11-21 04:07PM	Protagonist Stock Flashes This Positive Signal After FDA Lifts Hold On Blood Diseases Drug Investor's Business Daily +93.86%
12:04PM	28 Stocks Moving In Monday's Mid-Day Session Benzinga
08:11AM	Protagonist Therapeutics shares soar after FDA lifts clinical hold on its experimental cancer drug MarketWatch
07:00AM	Protagonist Therapeutics Announces Removal of FDA Clinical Hold on the Rusfertide Clinical Development Program PR Newswire
Oct-04-21 07:00AM	Protagonist Therapeutics Announces Data from Phase 2 Rusfertide Study in Hereditary Hemochromatosis Selected for Oral Presentation at the Annual AASLD Meeting PR Newswire
Sep-23-21 11:00AM	Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Protagonist Therapeutics, Inc. (PTGX) Investigation ACCESSWIRE +16.35%
Sep-22-21 09:11PM	PROTAGONIST ALERT: Bragar Eagel & Squire, P.C. is Investigating Protagonist on Behalf of Protagonist Stockholders and Encourages Investors to Contact the Firm Business Wire
11:40AM	Investigation Alert: Kessler Topaz Meltzer & Check, LLP is Investigating Securities Fraud Claims on Behalf of Protagonist Therapeutics, Inc. (NASDAQ: PTGX) Investors GlobeNewswire
07:59AM	Protagonist Therapeutics (PTGX) Moves 18.2% Higher: Will This Strength Last? Zacks
Sep-21-21 02:58PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Protagonist Therapeutics, Inc. - PTGX Newsfile +18.22%
Sep-20-21 04:14PM	Why Protagonist Therapeutics Stock Plunged Today Motley Fool -26.13%
Sep-17-21 04:06PM	Highly Rated Protagonist Stock Takes A Hit After Study Mice Develop Tumors Investor's Business Daily -62.00%
03:10PM	Mid-Afternoon Market Update: Nasdaq Down 1%; Protagonist Therapeutics Shares Plummet Benzinga
02:48PM	Why Protagonist Therapeutics Stock Is Tanking Today Motley Fool
12:12PM	Mid-Day Market Update: Crude Oil Falls Over 1%; Helbiz Shares Spike Higher Benzinga
07:00AM	Protagonist Therapeutics Reports FDA Clinical Hold on Rusfertide Clinical Development Program PR Newswire
Sep-15-21 05:05PM	Protagonist Therapeutics Reports Granting of Inducement Awards PR Newswire
Sep-07-21 07:00AM	Protagonist Therapeutics Appoints Scott Plevy, M.D., Executive Vice President and Therapeutic Head, Gastroenterology PR Newswire
Aug-10-21 08:05AM	Protagonist Therapeutics Announces Resolution of Contract Dispute with Zealand Pharma PR Newswire
01:53AM	Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Analysts Are More Bearish Than They Used To Be Simply Wall St.
Aug-04-21 06:45PM	Protagonist Therapeutics (PTGX) Reports Q2 Loss, Lags Revenue Estimates Zacks
04:05PM	Protagonist Therapeutics Reports Second Quarter 2021 Financial Results and Recent Company Progress PR Newswire
Jul-29-21 03:05PM	Will Protagonist Therapeutics (PTGX) Report Negative Q2 Earnings? What You Should Know Zacks
Jul-28-21 04:05PM	Protagonist Therapeutics Announces Amendment of Agreement with Janssen Biotech for the Continued Development and Commercialization of IL-23 Antagonists PR Newswire
Jul-21-21 04:32AM	Protagonist Therapeutics, Inc. (PTGX) Fell Out Of Favor With Hedge Funds Insider Monkey
Jul-06-21 07:17AM	If You Had Bought Protagonist Therapeutics (NASDAQ:PTGX) Stock Three Years Ago, You Could Pocket A 554% Gain Today Simply Wall St.
Jun-30-21 04:27PM	Protagonist Therapeutics Reports Granting of Inducement Award PR Newswire
Jun-18-21 04:05PM	Protagonist Therapeutics, Inc. Announces Closing of $132.2 Million Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares PR Newswire
Jun-17-21 08:57AM	Protagonist Therapeutics (PTGX) Stock Jumps 9.3%: Will It Continue to Soar? Zacks
Jun-16-21 06:53AM	Protagonist Therapeutics Secures $115M Via Equity Raise Benzinga +9.33%
Jun-15-21 09:07PM	Protagonist Therapeutics Announces Pricing of $115 Million Upsized Public Offering of Common Stock PR Newswire -7.20%
Jun-14-21 05:00PM	Protagonist Therapeutics Announces Proposed Public Offering of Common Stock PR Newswire
09:38AM	Company News for Jun 14, 2021 Zacks
Jun-11-21 02:09PM	Protagonist Stock Moves Higher As Rusfertide Shows Durability Of Effect, Symptom Improvements In Blood Cancer Trial Benzinga +17.14%
07:00AM	Protagonist Therapeutics Announces Updated Phase 2 Data Supporting Long-Term Efficacy of Rusfertide in Polycythemia Vera PR Newswire
Jun-07-21 07:06AM	Protagonist Therapeutics to Host Investor Conference Call and Webcast to Discuss Updated Phase 2 Rusfertide Results in Polycythemia Vera as Presented at EHA 2021 PR Newswire
Jun-03-21 07:00AM	Protagonist Therapeutics Receives FDA Breakthrough Therapy Designation for Rusfertide in Polycythemia Vera PR Newswire
May-24-21 07:00AM	Protagonist Therapeutics Announces First Subject Dosed in Phase 1 Study of Oral IL-23 Receptor Antagonist PN-232 PR Newswire
May-21-21 10:59AM	2 Momentum Stocks With Potential for Further Gains TipRanks
May-12-21 11:14AM	Protagonist Therapeutics Announces Presentation of Updated Results from Phase 2 Study of Rusfertide in Polycythemia Vera, Selected for Oral Presentation at EHA 2021 PR Newswire
May-04-21 06:20PM	Protagonist Therapeutics (PTGX) Reports Q1 Loss, Tops Revenue Estimates Zacks
04:01PM	Protagonist Reports First Quarter 2021 Financial Results and Provides Corporate Update PR Newswire
May-03-21 05:47PM	Protagonist Therapeutics Reports Granting of Inducement Award PR Newswire
Apr-27-21 07:00AM	Protagonist Therapeutics Completes Enrollment for Phase 2 Study of Rusfertide in Polycythemia Vera and Announces Plans for Data Update at an Upcoming Medical Meeting PR Newswire
Apr-24-21 05:08PM	Is PTGX Stock A Buy or Sell? Insider Monkey
Apr-07-21 08:47AM	Protagonist Therapeutics (NASDAQ:PTGX) Is In A Good Position To Deliver On Growth Plans Simply Wall St.
Mar-22-21 04:01PM	Protagonist Announces Plans to Initiate a Global Phase 3 Study for Rusfertide in Polycythemia Vera Following Interactions with the U.S. Food & Drug Administration and the European Medicines Agency PR Newswire
08:03AM	Protagonist Therapeutics (PTGX) Soars 5.9%: Is Further Upside Left in the Stock? Zacks
Mar-10-21 05:55PM	Protagonist Therapeutics (PTGX) Reports Q4 Loss, Tops Revenue Estimates Zacks
04:01PM	Protagonist Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Corporate Update PR Newswire
01:30PM	Protagonist Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
Mar-03-21 07:00AM	Protagonist Therapeutics to Announce Fourth Quarter and Full Year 2020 Financial Results PR Newswire
Mar-02-21 12:30PM	Will Protagonist Therapeutics (PTGX) Report Negative Q4 Earnings? What You Should Know Zacks +9.72%
07:00AM	Protagonist Therapeutics to Participate in the H.C. Wainwright Global Life Sciences Conference PR Newswire
Feb-26-21 06:19PM	Protagonist Therapeutics Reports Granting of Inducement Award PR Newswire
Feb-16-21 07:00AM	Protagonist Therapeutics to Participate in the SVB Leerink Virtual 10th Annual Global Healthcare Conference PR Newswire
Jan-29-21 06:22PM	Protagonist Therapeutics Reports Granting of Inducement Award PR Newswire
Jan-07-21 04:18AM	Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Insiders Increased Their Holdings Simply Wall St. +7.47%

Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with polycythemia vera and hereditary hemochromatosis, as well as for the treatment of other blood disorders; PN-943, an oral, alpha-4-beta-7 integrin- specific antagonist peptide that is in Phase II clinical trials for treating inflammatory bowel disease (IBD); and PN-235, an orally delivered interleukin-23 receptor specific antagonist for the treatment of IBD and non-IBD indications. The company has a license and collaboration agreement with Janssen Biotech, Inc. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
PATEL DINESH V PH D	President and CEO	May 04	Option Exercise	4.21	15,742	66,274	584,048	May 04 08:33 PM
Waddill William D.	Director	May 03	Option Exercise	8.59	12,000	103,080	12,000	May 04 08:41 PM
Gupta Suneel	Chief Development Officer	Apr 26	Option Exercise	7.38	40,000	295,200	117,561	Apr 26 09:42 PM
PATEL DINESH V PH D	President and CEO	Apr 26	Option Exercise	4.21	30,000	126,300	568,306	Apr 26 09:34 PM
PATEL DINESH V PH D	President and CEO	Apr 14	Option Exercise	1.89	34,087	64,424	537,847	Apr 14 08:09 PM
PATEL DINESH V PH D	President and CEO	Dec 21	Sale	32.14	15,000	482,170	477,158	Dec 23 04:17 PM
PATEL DINESH V PH D	President and CEO	Sep 21	Option Exercise	4.21	40,000	168,400	492,158	Sep 21 09:45 PM
Liu David Y	Chief Scientific Officer	Aug 17	Option Exercise	0.87	10,000	8,700	73,033	Aug 19 05:49 PM
Liu David Y	Chief Scientific Officer	Aug 17	Sale	47.56	14,779	702,889	58,254	Aug 19 05:49 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience